Project Grant R01AI183405
Award Date
6/18/24
Completion Date
5/31/29
Dollars Obligated
$134K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Peru
Similar Awards
This $256,504 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) will support a Phase 2C randomized, controlled, open-label clinical trial. The trial aims to evaluate novel 4-month treatment regimens for isoniazid-monoresistant tuberculosis (IMR-TB) compared to the current 6-month standard of care. The key objectives are to assess time to sputum culture conversion, proportion of grade...
This $787,171 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports the development of novel compounds to treat tuberculosis (TB). The primary awardee, The Washington University, is leading efforts to identify and optimize 1,2,4-triazole and pyrrolidine compounds that demonstrate potent anti-TB activity, including against drug-resistant strains. Key objectives include...
This $817,405 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) aims to develop new 3-4 drug regimens consisting of the inhaled spectinamide drug 1810 (DP1810) combined with other oral TB drugs for the treatment of drug-sensitive and multidrug-resistant tuberculosis (TB). The key activities include: 1) manufacturing and characterizing DP1810 for inhalation therapy, 2) determining the...
This $2,817,044 Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports a comprehensive research program to investigate the complex host-pathogen interactions that influence tuberculosis (TB) infection outcomes. The program leverages novel mouse genetic resources and large panels of Mycobacterium tuberculosis (MTB) strains to study how the combinatorial complexity of host and bacterial diversity...
This $2,935,025 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) aims to develop an effective therapeutic vaccine for preventing relapse and reinfection of drug-resistant tuberculosis (TB). The research, conducted by Seattle Children's Hospital, will screen 16 vaccine candidates comprising 4 subunit antigens and 4 adjuvants, evaluating their safety and efficacy in mouse and guinea...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to develop pro-apoptotic (cell-killing) drugs as host-directed therapies for pulmonary tuberculosis (TB). The $774,881 award will fund a 5-year project to evaluate how these novel drug therapies, such as the BCL-2 inhibitor navitoclax, can shorten TB treatment duration, improve bacterial clearance, and...
This federal Project Grant award, totaling $843,516 and awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports a clinical pharmacology study to confirm optimal dosing of tuberculosis (TB) preventive therapy (TPT) in populations at high risk for TB, including people living with HIV (PLHIV) taking dolutegravir, children under 12, and pregnant individuals. The study, titled "SHORT-COURSE...
This $193,375 Project Grant was awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant aims to identify genetic drivers of the ESX1 secretion system in Mycobacterium tuberculosis (Mtb) that may contribute to variable treatment responses, even in drug-sensitive TB cases. The research project has two key objectives: 1) Use bacterial genetic approaches to assess the effects of clinically...
This Project Grant award, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to characterize the burden, severity, and phenotypic presentation of post-tuberculosis lung disease (PTLD) and its association with interleukin-6 (IL-6) signaling pathways in tuberculosis (TB) patients with and without HIV. The $743,698 award, which runs from September 20, 2024 to August 31, 2029, will leverage an...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $766,877 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Albert Einstein College of Medicine in Bronx, NY. The project aims to conduct a pragmatic, randomized controlled trial to evaluate the efficacy of therapeutic drug monitoring (TDM) in preventing premature discontinuation of the antibiotic linezolid for the treatment of rifampin-resistant tuberculosis (RR-TB). The study will...